241 related articles for article (PubMed ID: 36111676)
1. Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV).
Abdul Massih S; Eke AC
Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1413-1424. PubMed ID: 36111676
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
3. Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.
Freriksen JJM; van Seyen M; Judd A; Gibb DM; Collins IJ; Greupink R; Russel FGM; Drenth JPH; Colbers A; Burger DM
Aliment Pharmacol Ther; 2019 Oct; 50(7):738-750. PubMed ID: 31448450
[TBL] [Abstract][Full Text] [Related]
4. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.
Dobrowolska K; Brzdęk M; Rzymski P; Flisiak R; Pawłowska M; Janczura J; Brzdęk K; Zarębska-Michaluk D
Expert Opin Pharmacother; 2024 May; 25(7):833-852. PubMed ID: 38768013
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Virus in Pregnancy: An Opportunity to Test and Treat.
Fogel RS; Chappell CA
Obstet Gynecol Clin North Am; 2023 Jun; 50(2):363-373. PubMed ID: 37149316
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review.
Rana R; Dangal R; Singh Y; Gurung RB; Rai B; Sharma AK
JNMA J Nepal Med Assoc; 2021 Sep; 59(241):942-953. PubMed ID: 35199739
[TBL] [Abstract][Full Text] [Related]
8. Evidence for Implementation: HIV/HCV Coinfection and Pregnancy.
Curtis MR; Chappell C
Curr HIV/AIDS Rep; 2023 Feb; 20(1):1-8. PubMed ID: 36652107
[TBL] [Abstract][Full Text] [Related]
9. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
[TBL] [Abstract][Full Text] [Related]
10. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
Du P; Wang X; Kong L; Jung J
Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
[No Abstract] [Full Text] [Related]
11. Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
Cervino L; Hynicka LM
Ann Pharmacother; 2018 Nov; 52(11):1152-1157. PubMed ID: 29681166
[TBL] [Abstract][Full Text] [Related]
12. Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.
Jafari A; Khalili H; Izadpanah M; Dashti-Khavidaki S
Expert Opin Drug Saf; 2015 May; 14(5):713-31. PubMed ID: 25813487
[TBL] [Abstract][Full Text] [Related]
13. Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
Hachicha-Maalej N; Collins IJ; Ades AE; Scott K; Judd A; Mostafa A; Chappell E; Hamdy-El-Sayed M; Gibb D; Pett S; Mariné-Barjoan E; Volokha A; Yazdanpanah Y; Deuffic-Burban S
J Hepatol; 2023 May; 78(5):937-946. PubMed ID: 36669704
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection.
Néant N; Solas C
Int J Antimicrob Agents; 2020 Jul; 56(1):105571. PubMed ID: 30394302
[TBL] [Abstract][Full Text] [Related]
15. Managing hepatitis C therapy failures and chronic kidney disease.
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1135-1142. PubMed ID: 30309263
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Rivero-Juarez A; Brieva T; Frias M; Rivero A
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
18. Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients.
Macías J; Neukam K; Merchante N; Pineda JA
Expert Opin Pharmacother; 2014 Sep; 15(13):1837-48. PubMed ID: 25085577
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
[TBL] [Abstract][Full Text] [Related]
20. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).
Scavone C; Sportiello L; Rafaniello C; Mascolo A; Sessa M; Rossi F; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):85-100. PubMed ID: 27875916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
